TABLE OF CONTENTS
1 INTRODUCTION 52
1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA VENOUS DISEASES TREATMENT MARKET 52
1.4 CURRENCY AND PRICING 54
1.5 LIMITATIONS 55
1.6 MARKETS COVERED 55
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 DBMR TRIPOD DATA VALIDATION MODEL 63
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.6 MULTIVARIATE MODELLING 67
2.7 MARKET END USER COVERAGE GRID 68
2.8 INSTRUMENT BASED LIFELINE CURVE 69
2.9 DBMR MARKET POSITION GRID 70
2.10 VENDOR SHARE ANALYSIS 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
4 PREMIUM INSIGHTS 77
4.1 PESTEL ANALYSIS 78
4.2 PORTER'S FIVE FORCES 79
5 MIDDLE EAST & AFRICA VENOUS DISEASES TREATMENT MARKET, INDUSTRY INSIGHTS 80
6 EPIDEMIOLOGY 82
7 REGULATORY FRAMEWORK 83
8 MARKET OVERVIEW 86
8.1 DRIVERS 88
8.1.1 RISING INCIDENCES OF VENOUS DISEASES 88
8.1.2 RAPID CHANGES IN LIFESTYLE LEAD TO OBESITY RESULTING IN VENOUS DISEASES 88
8.1.3 INCREASE IN THE GERIATRIC POPULATION 89
8.1.4 TECHNOLOGICALLY ADVANCEMENT IN THE TREATMENT OF VENOUS DISEASES 90
8.2 RESTRAINTS 91
8.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 91
8.2.2 INADEQUATE REIMBURSEMENT COVERAGE 91
8.3 OPPORTUNITIES 92
8.3.1 RISING AWARENESS TOWARDS VENOUS DISORDERS 92
8.3.2 NEED FOR PROPER DIAGNOSIS AND TREATMENT OF VENOUS DISEASES 92
8.3.3 GROWING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES 93
8.3.4 OCCUPATIONAL LIFESTYLE INCREASES THE NEED FOR VENOUS DISEASE TREATMENT 93
8.4 CHALLENGES 94
8.4.1 HIGH COST ASSOCIATED WITH VENOUS DISEASE TREATMENT 94
8.4.2 SIDE EFFECTS AND RISK ASSOCIATED WITH DIFFERENT TREATMENT MODES 95
9 MIDDLE EAST & AFRICA VENOUS DISEASES TREATMENT MARKET, BY PRODUCT TYPE 96
9.1 OVERVIEW 97
9.2 SCLEROTHERAPY INJECTION 100
9.2.1 SCLEROTHERAPY, BY TYPE 100
9.2.1.1 INTRAVENOUS 101
9.2.1.2 INTRADERMAL 101
9.2.1.3 SUBCUTANEOUS 101
9.2.2 SUBCUTANEOUS, BY APPLICATION 101
9.2.2.1 MALFORMED LYMPHED VESSELS 101
9.2.2.2 HEMORRHOIDS 101
9.2.2.3 HYDROCELES 101
9.2.2.4 OTHERS 101
9.3 ABLATION DEVICES 101
9.3.1 THERMAL ABLATION 102
9.3.1.1 RADIOFREQUENCY 103
9.3.1.1.1 CATHETER MANIPULATION SYSTEMS 103
9.3.1.1.2 TEMPERATURE CONTROLLED 103
9.3.1.1.3 FLUID COOLED 104
9.3.1.2 LIGHT 104
9.3.1.2.1 EXCIMER LASERS 104
9.3.1.2.2 COLD LASERS 104
9.3.1.3 ULTRASOUND 104
9.3.1.3.1 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) 105
9.3.1.3.2 SHOCK WAVE LITHOTRIPSY 105
9.3.1.3.3 MAGNETIC RESONANCE IMAGING GUIDED FOCUSED ULTRASOUND (MRI-FUS) 105
9.3.1.3.4 ULTRASONIC SURGICAL SYSTEMS 105
9.3.1.4 RADIATION 105
9.3.1.4.1 STEREOTACTIC BODY RADIATION THERAPY 106
9.3.1.4.2 INTENSITY-MODULATED RADIATION THERAPY 106
9.3.1.4.3 STEREOTACTIC RADIOTHERAPY & RADIOSURGERY 106
9.3.1.4.4 IMAGE GUIDED RADIATION THERAPY 106
9.3.1.4.5 INTRAVASCULAR BRACHYTHERAPY 106
9.3.1.4.6 PROTON BEAM THERAPY 106
9.3.1.5 ELECTRICAL 106
9.3.1.5.1 ELECTRICAL ABLATORS 107
9.3.1.5.2 ELECTRONIC BRACHYTHERAPY 107
9.3.1.6 MICROWAVE 107
9.3.1.7 HYDROTHERMAL 107
9.3.2 NON-THERMAL ABLATION 107
9.3.2.1 CRYOABLATION 107
9.3.2.1.1 EPIDERMAL AND SUBCUTANEOUS CRYOABLATION DEVICES 108
9.3.2.1.2 CRYOGEN SPRAY PROBE 108
9.3.2.1.3 TISSUE CONTACT PROBE 108
9.3.2.2 HYDROMECHANICAL ABLATION 108
9.4 VENOUS CLOSURE PRODUCTS 108
9.4.1 VENOUS CLOSURE PRODUCTS, BY PROCEDURE 109
9.4.1.1 INTERVENTIONAL CARDIOLOGY 109
9.4.1.2 INTERVENTIONAL RADIOLOGY 109
9.4.2 VENOUS CLOSURE PRODUCTS, BY TECHNOLOGY 109
9.4.2.1 FEMORAL ACCESS TECHNIQUE 110
9.4.2.2 RADIAL ACCESS TECHNIQUE 110
9.5 VENOUS STENTS 110
9.5.1 VENOUS STENTS, BY TECHNOLOGY 111
9.5.1.1 WALLSTENT TECHNOLOGY 111
9.5.1.2 ILIAC VEIN STENT TECHNOLOGY 111
9.5.2 VENOUS STENTS, BY APPLICATION 111
9.5.2.1 LEG 112
9.5.2.2 CHEST 112
9.5.2.3 ABDOMEN 112
9.5.2.4 OTHERS 112
9.6 MEDICATION 112
9.7 OTHERS 113
10 MIDDLE EAST & AFRICA VENOUS DISEASES TREATMENT MARKET, BY DISEASE TYPE 114
10.1 OVERVIEW 115
10.2 VARICOSE VEINS 118
10.3 DEEP VEIN THROMBOSIS (DVT) 118
10.4 PULMONARY EMBOLISM 119
10.5 CHRONIC VENOUS INSUFFICIENCY (CVI) 120
10.6 SUPERFICIAL THROMBOPHLEBITIS 120
10.7 OTHERS 121
11 MIDDLE EAST & AFRICA VENOUS DISEASES TREATMENT MARKET, BY TREATMENT TYPE 123
11.1 OVERVIEW 124
11.2 SCLEROTHERAPY 127
11.3 RADIOFREQUENCY ABLATION THERAPY 127
11.4 LASER TREATMENT 128
11.5 AMBULATORY PHLEBECTOMY 129
11.6 VEIN LIGATION AND STRIPPING 129
11.7 ANGIOPLASTY OR STENTING 130
11.8 SURGERIES 131
11.9 COMPRESSION THERAPY 131
11.10 VEINACTIVE MEDICATION 132
11.11 VENA CAVA FILTER 133
11.12 OTHER THERAPIES 134
12 MIDDLE EAST & AFRICA VENOUS TREATMENT DISEASES MARKET, BY END USER 135
12.1 OVERVIEW 136
12.2 HOSPITALS 139
12.3 CLINICS 139
12.4 AMBULATORY SURGICAL CENTERS 140
12.5 OTHERS 141
13 MIDDLE EAST & AFRICA VENOUS DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 142
13.1 OVERVIEW 143
13.2 DIRECT TENDER 146
13.3 RETAIL SALES 146
13.4 OTHERS 147
14 MIDDLE EAST & AFRICA VENOUS DISEASES TREATMENT MARKET, BY REGION 148
14.1 MIDDLE EAST & AFRICA 149
14.1.1 SOUTH AFRICA 160
14.1.2 SAUDI ARABIA 166
14.1.3 U.A.E. 172
14.1.4 EGYPT 178
14.1.5 ISRAEL 184
14.1.6 REST OF MIDDLE EAST AND AFRICA 190
15 MIDDLE EAST & AFRICA VENOUS DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 191
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 191
16 SWOT ANALYSIS 192
17 COMPANY PROFILE 193
17.1 MEDTRONIC 193
17.1.1 COMPANY SNAPSHOT 193
17.1.2 REVENUE ANALYSIS 193
17.1.3 COMPANY SHARE ANALYSIS 194
17.1.4 PRODUCT PORTFOLIO 194
17.1.5 RECENT DEVELOPMENTS 194
17.2 BOSTON SCIENTIFIC CORPORATION 195
17.2.1 COMPANY SNAPSHOT 195
17.2.2 REVENUE ANALYSIS 195
17.2.3 COMPANY SHARE ANALYSIS 196
17.2.4 PRODUCT PORTFOLIO 196
17.2.5 RECENT DEVELOPMENTS 197
17.3 VARIAN MEDICAL SYSTEMS, INC. 198
17.3.1 COMPANY SNAPSHOT 198
17.3.2 COMPANY SHARE ANALYSIS 198
17.3.3 PRODUCT PORTFOLIO 199
17.3.4 RECENT DEVELOPMENT 199
17.4 STRYKER 200
17.4.1 COMPANY SNAPSHOT 200
17.4.2 REVENUE ANALYSIS 200
17.4.3 COMPANY SHARE ANALYSIS 201
17.4.4 PRODUCT PORTFOLIO 201
17.4.5 RECENT DEVELOPMENT 201
17.5 KONINKLIJKE PHILIPS N.V. 202
17.5.1 COMPANY SNAPSHOT 202
17.5.2 REVENUE ANALYSIS 202
17.5.3 COMPANY SHARE ANALYSIS 203
17.5.4 PRODUCT PORTFOLIO 203
17.5.5 RECENT DEVELOPMENT 203
17.6 ABBOTT 204
17.6.1 COMPANY SNAPSHOT 204
17.6.2 REVENUE ANALYSIS 204
17.6.3 PRODUCT PORTFOLIO 205
17.6.4 RECENT DEVELOPMENT 205
17.7 ALMA LASERS 206
17.7.1 COMPANY SNAPSHOT 206
17.7.2 PRODUCT PORTFOLIO 206
17.7.3 RECENT DEVELOPMENT 206
17.8 ANGIODYNAMICS 207
17.8.1 COMPANY SNAPSHOT 207
17.8.2 REVENUE ANALYSIS 207
17.8.3 PRODUCT PORTFOLIO 208
17.8.4 RECENT DEVELOPMENT 208
17.9 B.BRAUN MELSUNGEN AG 209
17.9.1 COMPANY SNAPSHOT 209
17.9.2 REVENUE ANALYSIS 209
17.9.3 PRODUCT PORTFOLIO 210
17.9.4 RECENT DEVELOPMENTS 210
17.10 BAYLIS MEDICAL COMPANY, INC 211
17.10.1 COMPANY SNAPSHOT 211
17.10.2 PRODUCT PORTFOLIO 211
17.10.3 RECENT DEVELOPMENT 211
17.11 BD 212
17.11.1 COMPANY SNAPSHOT 212
17.11.2 REVENUE ANALYSIS 212
17.11.3 PRODUCT PORTFOLIO 213
17.11.4 RECENT DEVELOPMENT 213
17.12 CANDELA MEDICAL 214
17.12.1 COMPANY SNAPSHOT 214
17.12.2 PRODUCT PORTFOLIO 214
17.12.3 RECENT DEVELOPMENT 214
17.13 CARL ZEISS MEDITEC AG 215
17.13.1 COMPANYSNAPSHOT 215
17.13.2 REVENUE ANALYSIS 215
17.13.3 PRODUCT PORTFOLIO 216
17.13.4 RECENT DEVELOPMENT 216
17.14 COOK 217
17.14.1 COMPANY SNAPSHOT 217
17.14.2 PRODUCT PORTFOLIO 217
17.14.3 RECENT DEVELOPMENTS 217
17.15 IMRICOR 218
17.15.1 COMPANY SNAPSHOT 218
17.15.2 REVENUE ANALYSIS 218
17.15.3 PRODUCT PORTFOLIO 219
17.15.4 RECENT DEVELOPMENT 219
17.16 OLYMPUS CORPORATION 220
17.16.1 COMPANY SNAPSHOT 220
17.16.2 REVENUE ANALYSIS 220
17.16.3 PRODUCT PORTFOILIO 221
17.16.4 RECENT DEVELOPMENT 221
17.17 OPTIMED MEDIZINISCHE INSTRUMENTE GMBH 222
17.17.1 COMPANY SNAPSHOT 222
17.17.2 PRODUCT PORTFOLIO 222
17.17.3 RECENT DEVELOPMENTS 222
17.18 PLUSMEDICA.DE 223
17.18.1 COMPANY SNAPSHOT 223
17.18.2 PRODUCT PORTFOLIO 223
17.18.3 RECENT DEVELOPMENT 223
17.19 SCITECH 224
17.19.1 COMPANY SNAPSHOT 224
17.19.2 PRODUCT PORTFOLIO 224
17.19.3 RECENT DEVELOPMENTS 224
17.20 SMITH + NEPHEW 225
17.20.1 COMPANY SNAPSHOT 225
17.20.2 REVENUE ANALYSIS 225
17.20.3 PRODUCT PORTFOLIO 226
17.20.4 RECENT DEVELOPMENT 226

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.